Jaume Mora

Jaume Mora is a Clinical Professor in the Department of Pediatrics at the University of Barcelona, specializing in Pediatric and Molecular Oncology. He earned a PhD in Molecular Oncology (2003) following residency training in general pediatrics (1992-1995) and a pediatric Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), New York (1996-1998). He later completed a Research Fellowship in molecular pathology at MSKCC (1999-2001) before returning to Barcelona in 2002 as a leader in pediatric oncology.

• PhD in Molecular Oncology (2003)
• Residency: General Pediatrics (1992-1995)
• Fellowship: Pediatric Hematology/Oncology at MSKCC (1996-1998)
• Research Fellowship: Molecular Pathology at MSKCC (1999-2001)

His research focuses on pediatric cancers like neuroblastoma and Ewing sarcoma, with emphasis on molecular pathology, targeted therapies, and cancer immunotherapy. Recent work explores HDAC6 inhibition in Ewing sarcoma, AKT inhibitors for vascular malformations, and extracellular vesicle-mediated tumor-stromal interactions.

Key contributions include clinical trials on naxitamab for high-risk neuroblastoma, highlighting its efficacy and safety. His publications span journals like Annals of Oncology, Oncogene, and Translational Research, reflecting interdisciplinary collaboration.